Beverley Carr is CBO at Amphista Therapeutics

Wednesday 10 November 2021
Amphista Therapeutics Ltd
Appointee name
Beverley Carr

United Kingdom

Beverley Carr, a scientist with commercial experience, has been appointed chief business officer at Amphista Therapeutics Ltd which is developing therapies based on targeted protein degradation. She joins from Achilles Therapeutics Plc, a company developing T cell therapies for cancer, where she was also CBO. Prior to this she headed business development for the immunoinflammation therapy area at GlaxoSmithKline Plc.

Dr Carr received a DPhil in chemistry from the University of Oxford and an MBA from the University of Cambridge, UK.

Amphista Therapeutics announced the appointment on 1 November 2021.

Copyright 2021 Evernow Publishing Ltd